The development of a long-acting ondansetron formulation, RedHill Biopharma Ltd.’s Bekinda 24 mg once-daily extended-release tablets, for gastroenteritis, could change the way healthcare professionals deal with norovirus and other debilitating but self-limiting infectious gastroenteritis outbreaks, that are associated with high rates of emergency room admissions, and re-admissions.
RedHill BioPharma, an emerging US/Israeli specialty pharmaceutical company, has just released positive top-line results from the Phase III GUARD study of Bekinda showing the anti-nausea therapy met its primary endpoint in patients with acute gastroenteritis and gastritis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?